The Acumen Pharmaceuticals Inc (NASDAQ: ABOS) stock price soared 79.6% after releasing positive topline data from its Phase 1 INTERCEPT-AD trial of ACU193, the first clinical-stage amyloid beta oligomers (AβO) targeting antibody therapy in early Alzheimer's Disease (AD).
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Investors reacted positively to the positive clinical trial data as it met the primary and secondary targets demonstrating proof-of-mechanism for ACU193. The Phase 1 trial was a first-in-human, randomised, double-blind, placebo-controlled study in both single and multiple doses in 60 participants with early AD.
Top Broker Recommendation
- BlackBull 26,000+ Shares, Options, ETFs, Bonds, and other underlying assets – Read our Review
- Admiral Markets More than 4500 stocks & over 200 ETFs available to invest in – Read our Review
- Hargreaves Lansdown The company's website is easily understandable and accessible to a wide range of customers – Read our Review
- eToro Wide range of instruments available to trade – Read our Review
- IG Top-tier regulation – Read our Review
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY
The study revealed that ACU193 was generally well-tolerated with a compelling overall safety profile, meeting the primary objective of this Phase 1 trial. The data showed that higher doses of ACU193 showed a statistically significant reduction in amyloid plaque load as determined by amyloid PET after 6-12 weeks.
Daniel O'Connell, Acumen Phama’s President and CEO, said: “ACU193's observed dose-related central target engagement, rapid reduction of amyloid plaque and compelling safety profile validate our confidence in ACU193's differentiated mechanism of action: selectively targeting amyloid beta oligomers.”
ACU193 is a humanised monoclonal antibody (mAb) discovered and developed based on its selectivity for soluble AβOs, which Acumen believes are the most toxic and pathogenic form of Aβ, relative to Aβ monomers and amyloid plaques.
Soluble AβOs have been observed to be potent neurotoxins that bind to neurons, inhibit synaptic function and induce neurodegeneration.
By selectively targeting toxic soluble AβOs, ACU193 aims to directly address a growing body of evidence indicating that soluble AβOs are a primary underlying cause of the neurodegenerative process in Alzheimer’s disease.
ACU193 has been granted Fast Track designation for treating early Alzheimer’s disease by the U.S. Food and Drug Administration. Acumen Pharma intends to work with FDA in Q4 to map out the future development of ACU193.
*This is not investment advice.
Acumen Pharma (ABOS) share price.
The Acumen Pharma (ABOS) stock price soared 79.62% to trade at $11.28, from Friday’s closing price of $6.28.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
